Pet in oncology ii - other tumours

Nuclear Medicine Communications

Volumn 21, Issue 3, 2000, Pages 229-233

  Nunan, T O ^a   Hain, S F ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXPERIMENTAL NEOPLASM; HUMAN; METHODOLOGY; NEOPLASM; REVIEW; SCINTISCANNING;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034152477     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200003000-00005     Document Type: Article

References (41)

1. Nuutinen J, Leskinen S, Lindholm P et al. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med 1998; 25: 729-735.
2. Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 199: 111-116.
3. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: Role of whole body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
4. Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun 1999; 20: 13-20.
5. Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin’s lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 446-471.
6. de Wit M, Brumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8: S57-S60.
7. Karp JS, Muehlleher G, Qu H, Yan XH. Singles transmission in volume-imaging PET with 137Cs source. Phys Med Biol 1995; 40: 929-944.
8. Alazraki N, Eshima D, Eshima LA et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer and other potential cancers. Sem Nucl Med 1997; 27: 55-67.
9. Damian DL, Fulham MJ, Thompson E, Thompson JF. PET in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 329.
10. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow up of high risk melanoma patients with whole body 18 FDG PET: Results of a prospective study of 100 patients. Cancer 1998; 82: 166-171.
11. Holder WD, White RL, Zuger JH, Easton EJ, Green FL. Effectiveness of PET for the detection of melanoma metastases. Ann Surg 1998; 227: 764-771.
12. Wagner JD, Schauwecker D, Davidson D et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 117: 1508-1522.
13. Blessing C, Feine U, Geiger H, Carl M, Rassner G, Fierlberck G. PET and ultrasonography: A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995; 131: 1394-1398.
14. Kirkwood JM, Strawderman M, Ernstoff MS et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern cooperative oncology group trial. J Clin Oncol 1996; 14: 7-17.
15. Boni R. Whole body PET: An accurate staging modality for metastatic melanoma. Arch Dermatol 1996; 132: 833-834.
16. Lucignani G, Paganelli G, Modorati G et al. MRI, antibody-guided scintigraphy and glucose metabolism in uveal melanoma. J Comput Assist Tomogr 1992; 16: 77-83.
17. Modorati G, Lucignani G, Landoni G et al. Glucose metabolism and pathological findings in uveal melanoma: Preliminary results. Nucl Med Commun 1996; 17: 1052-1056.
18. Flanagan FL, Dehdashti F, Siegel BA et al. Staging of esophageal cancer with 18FDG PET. Am J Roentgenol 1997; 168: 417-424.
19. Block MI, Patterson, GA, Sundaresan RS et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770-776.
20. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521-527.
21. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53: 659-665.
22. Couper GW, McAteer D, Wallis F et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85: 1403-1406.
23. Ichiya Y, Kuwabara Y, Otsuka M et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32: 1650-1660.
24. Gupta NC, Falk PM, Frank AL et al. Pre-operative staging of colorectal carcinoma using PET. Nebraska Med J 1993; 78: 30-35.
25. Schiepers C, Penninckz F, De Vadder N et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol 1995; 21: 517-522.
26. Ruhlmann J, Schomburg A, Bender H et al. FDG whole body PET in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997; 40: 1195-1204.
27. Ogunbiyi OA, Flanagan FI, Dehdashti F et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613-620.
28. Abdel-Nabi H, Doerr RJ, Lamonica DM et al. Staging of primary colorectal carcinomas with 18FDG whole body PET: Correlation with histopathological and CT findings. Radiology 1998; 206: 755-760.
29. Haberkorn U, Strauss LG, Dimitrakopoulou A et al. PET studies of FDG metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.
30. Beets G, Penninckz F, Schiepers C et al. Clinical value of whole body positron emission tomography with 18FDG in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-1670.
31. Vitola JV, Delbeke D, Sandler MP et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171: 21-26.
32. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38: 1196-1201.
33. Flanagan FL, Dehdashti F, Ogunbiyi OA et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319-323.
34. Hertel A, Mantaka P, Adams S et al. Whole-body FDG-PET performance for evaluation of cancer of unknown origin. Eur J Nucl Med 1998;: 974 (abstract).
35. Kole AC, Nieweg OE, Pruim J et al. Detection of unknown occult primary tumours using positron emission tomography. Cancer 1998; 82: 1160-1166.
36. Scheidhauer K, Jungehulsing M, Pietrzyk P et al. FDG-PET in patients with CUP syndrome. Eur J Nucl Med 1998;: 1021 (abstract).
37. Mead GM. Testis. In: Price P, Sikora K, eds. Treatment of cancer, 3rd edn. London: Chapman & Hall, 1995: 627-645.
38. Lassen U, Daugaard G, Rorth M, Eigtved A, Friberg L. Detection of metastatic disease with positron emission tomography in computed tomography negative non-seminomatous germ cell tumours. Proc ASCO 1997; 16: 1142.
39. Hain SF, O’Doherty MJ, Timothy AR, Partridge S, Leslie MD, Huddart RA. Fluorodeoxyglucose positron emission tomography in the initial staging of germ cell tumours. Eur J Nucl Med (in press).
40. Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998; 39: 815-822.
41. Hain SF, O’Doherty MJ, Huddart RA et al. Recurrent testicular carcinoma - the role of FDG-PET. Nucl Med Commun 1999; 20: 475.